Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial

Abstract

Risedronate 5 mg prevents bone loss in early postmenopausal women, is well tolerated, and represents an effective choice to maintain bone mass and prevent osteoporosis.

Treatment of postmenopausal osteoporosis in women: a systematic review

“…Harris et al 18 observed better efficacy in the treatment group at 5mg (p < 0.05), while at the end of the first year of the trial they detected low efficacy for risedronate at 2.5mg, leading to a change in the initial study design, excluding this group. Meanwhile Hooper et al 19 did not detect any difference between the three groups in the incidence of vertebral fractures (p > 0.05).…”

“…There was no statistically significant difference between the results when using the drug or placebo. Two authors compared risedronate 2.5 and 5mg/day to placebo 18,19 . Harris et al 18 observed better efficacy in the treatment group at 5mg (p < 0.05), while at the end of the first year of the trial they detected low efficacy for risedronate at 2.5mg, leading to a change in the initial study design, excluding this group.…”

“…The five studies evaluating the use of risedronate presented the two outcomes (vertebral fractures and lumbar spine BMD) 15,16,17,18,19 . In relation to vertebral fractures, the study comparing different doses (5mg/day and 35 and 50mg/ week), showed no statistically significant difference in incidence between the groups 15 .…”

Prevention of postmenopausal osteoporosis and associated fractures: Clinical evaluation of the choice between estrogen and bisphosphonates

“…Published placebo-controlled trials demonstrate the efficacy of bisphosphonates in increasing bone mineral density (BMD), suppressing bone resorption markers and reducing vertebral and hip fractures [54][55][56][57]. A lasting effect on bone turnover has been frequently reported after the discontinuation of bisphosphonates [58].…”

Assessment of the Relationship Between Age and the Effect of Risedronate Treatment in Women with Postmenopausal Osteoporosis: A Pooled Analysis of Four Studies

“…6 The annual incidence of hip fracture in Asia is predicted to increase to between 2 million and 3.3 million in 2050, rates more than 5 times as great as those in 1990. 5,6 Risedronate is a pyridinyl bisphosphonate that has been shown to be effective in the prevention and treatment of osteoporosis at a daily dose of 5 mg, [16][17][18][19][20][21][22][23] a once-a-week dose of 35 mg, 24 a dose of 75 mg on 2 consecutive days a month, 25 or a once-a-month dose of 150 mg. 26 Treatment with risedronate for 36 months reduced the risk of vertebral fractures by 41% and nonvertebral fractures by 39% relative to placebo in women with at least one existing vertebral fracture 17 and the risk of hip fractures by 40% relative to placebo in women aged 70 to 79 with osteoporosis. 22 Retrospective analyses showed that risedronate significantly reduced the incidence of nonvertebral and clinical vertebral fractures within 6 months.…”